63286-44-2

Usage

InChI:InChI=1/C11H12BrNO/c12-8-11(14)13-7-3-5-9-4-1-2-6-10(9)13/h1-2,4,6H,3,5,7-8H2

Upstream product

• 635-46-1 1,2,3,4-tetrahydroisoquinoline 
• 598-21-0 2-Bromoacetyl bromide 

Downstream Products

• 928313-99-9 rac-1-(3,4-dihydro-2H-quinolin-1-yl)-2-(1-phenyl-ethylamino)-ethanone trifluoroacetate 
• 928614-93-1 2-(diphenylmethylamino)-1-(1,2,3,4-tetrahydroquinolin-1-yl)ethan-1-one 
• 928313-98-8 (RS)-2-(1-methylbenzylamino)-1-(1,2,3,4-tetrahydroquinolin-1-yl)ethan-1-one 
• 928314-52-7 (R)-2-(1-methylbenzylamino)-1-(1,2,3,4-tetrahydroquinolin-1-yl)ethan-1-one 

Relevant academic research and scientific papers

Design, synthesis, in vitro antiproliferative evaluation and in silico studies of new VEGFR-2 inhibitors based on 4-piperazinylquinolin-2(1H)-one scaffold

Angiogenesis is essential in the growth of solid tumors which need oxygen and nutrients supply to grow in size. The VEGF/VEGFR-2 signaling pathway plays an important role in tumor angiogenesis. Sorafenib is an FDA approved cancer therapeutic with activity

A copper(II)-mediated radical cross-dehydrogenative coupling/sulfinic acid elimination approach to 2-quinolones

A new cyclisation procedure to prepare 4-carboxy-quinolin-2-ones via a one-pot Cu(II)-mediated radical cross-dehydrogenative coupling/sulfinic acid elimination of linear anilides is described. Extensions to more complex substrates are also reported as are

ORGANIC COMPOUNDS

The invention relates to novel diamines of the formula (I) in which all variables are as defined in the specification, in free base form or in acid addition salt form, to their preparation, to their use as medicaments and to medicaments comprising them.

BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS

The invention concerns a compound of the formula (I) wherein Ring A is heterocyclyl; m is 0-4 and each R1 is a group such as hydroxy, halo, trifluoromethyl and cyano; R2 is halo and n is 0-2; and each R4 is a group such as hydroxy, halo, trifluromethyl and cyano; p is 0-4; and R3 is amino or hydroxy; or pharmaceutically-acceptable salts or in-vivo-hydrolysable ester or amide thereof processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical condions mediated by histone deacetylase

N-acylpyrrolidines and medicaments for the treatment or prevention of disorders linked to CKK and to gastrin

The present invention relates to derivatives of formula: STR1 to their salts, to their preparation and to the medicaments containing them.

1,2,5,6-Tetrahydro-4H-pyrrolo(3,2,1-j)quinolin-2-ones

The invention discloses 1,2,5,6-tetrahydro-4H-pyrrolo-(3,2,1-ij)quinolin-2-ones having pharmacological activity in animals and useful as CNS depressant agents. The compounds may be prepared by treating a haloacetyl derivative of 1,2,3,4-tetrahydroquinoline with a Friedel-Crafts catalyst. The haloacetyl derivative of 1,2,3,4-tetrahydroquinoline may be prepared by reacting 1,2,3,4-tetrahydroquinoline with a haloacetyl halide at a mole ratio of 2:1 in the presence of an inert, organic solvent.